In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning

Aliabadi, Amin; Haghshenas, Mohammad Reza; Kiani, Razie; Koohi‑Hosseinabadi, Omid; Purkhosrow, Azar; Pirsalami, Fatema; Panjehshahin, Mohammad Reza; Erfani, Nasrollah

doi:10.1007/s00210-023-02722-z

Cited by 1 publication

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The negative control group was administered normal physiological saline. Upon the death of each mouse, we removed the tumors, and a pathologist verified the tumor tissues after preparing slides (Xu et al 2017 ; Aliabadi et al 2023 ).…”

Section: Methodsmentioning

confidence: 99%

“…One promising approach in the quest for new treatments is drug repositioning, which involves repurposing existing drugs with known pharmacodynamics and pharmacokinetics for new therapeutic purposes. This strategy can significantly reduce the time and financial resources required to bring new treatments to the market (Masuda et al 2020 ; Aliabadi et al 2023 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis

Aliabadi,

Haghshenas,

Kiani

et al. 2024

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Purpose Colon cancer is a prevalent cancer globally, representing approximately 10% of all cancer cases and accounting for 10% of all cancer-related deaths. Therefore, finding new therapeutic methods with high efficiency will be very valuable. Cromolyn (C), a common anti-allergic and mast cell membrane stabilizing drug, has recently shown valuable anti-cancer effects in several studies. This study was designed to investigate the anti-cancer activity of cromolyn on colon cancer in vitro and in vivo and to determine values such as selectivity index and survival effect. Methods HT-29 (colon cancer) and MCF-10 (normal epithelial) cell lines were treated with C and Doxorubicin (DOX; Positive control). IC50 values and the effects of C and DOX on apoptosis were explored using methyl thiazole diphenyl-tetrazolium bromide (MTT) assay and Annexin V/PI Apoptosis Assay Kit. To investigate in an animal study, colon cancer was subcutaneously induced by CT26 cells (mouse colon cancer) in bulb/c mice. Mice were treated with 0.05 LD50 intraperitoneal every other day for 35 days. After the death of mice, tumor volume, tumor weight, and survival rate were evaluated. Results C selectively and significantly suppressed the proliferation of cancer cells in a dose-dependent manner. The IC50 values for the MCF-10 and HT29 cell lines were 7.33 ± 0.78 μM and 2.33 ± 0.6 μM, respectively. Notably, the selective index (SI) highlighted that C displayed greater selectivity in inhibiting cancer cell growth compared to DOX, with SI values of 3.15 and 2.60, respectively. C exhibited higher effectiveness and selectivity in inducing apoptosis in cancer cells compared to DOX, with a significant p-value (61% vs. 52%, P-value ≤ 0.0001). Also, in mice bearing colon cancer, C reduced the tumor volume (6317 ± 1685mm3) and tumor weight (9.8 ± 1.6 g) compared to the negative control group (weight 12.45 ± 0.9 g; volume 7346 ± 1077) but these values were not statistically significant (P ≤ 0.05). Conclusion Our study showed that cromolyn is a selective and strong drug in inhibiting the proliferation of colon cancer cells. Based on our results, the efficacy of C in vitro analysis (MTT assays and apoptosis), as well as animal studies is competitive with the FDA-approved drug doxorubicin. C is very promising as a low-complication and good-efficacy drug for cancer drug repositioning. This requires clinical research study designs to comprehensively evaluate its anti-cancer effects.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%